Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy

• Published in: International journal of radiation oncology, biology, physics Vol. 99; no. 1; pp. 128 - 135
• Main Authors: Davuluri, Rajayogesh, Jiang, Wen, Fang, Penny, Xu, Cai, Komaki, Ritsuko, Gomez, Daniel R., Welsh, James, Cox, James D., Crane, Christopher H., Hsu, Charles C., Lin, Steven H.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2017
• Subjects: Adenocarcinoma - immunology; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - therapy; Carcinoma, Squamous Cell - immunology; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - therapy; Chemoradiotherapy - adverse effects; Chemoradiotherapy - methods; Esophageal Neoplasms - immunology; Esophageal Neoplasms - mortality; Esophageal Neoplasms - pathology; Esophageal Neoplasms - therapy; Fluorouracil - therapeutic use; Humans; Incidence; Kaplan-Meier Estimate; Lymphocyte Count; Lymphopenia - epidemiology; Lymphopenia - etiology; Lymphopenia - mortality; Middle Aged; Monocytes - drug effects; Monocytes - radiation effects; Neutrophils - drug effects; Neutrophils - radiation effects; Odds Ratio; Platinum Compounds - therapeutic use; Proportional Hazards Models; Proton Therapy; Radiotherapy Dosage; Regression Analysis; Retrospective Studies; T-Lymphocytes - drug effects; T-Lymphocytes - radiation effects; Taxoids - therapeutic use; Treatment Outcome

Host immunity may affect the outcome in patients with esophageal cancer. We sought to identify factors that influenced absolute lymphocyte count (ALC) nadir during chemoradiation therapy (CRT) for esophageal cancer (EC) and looked for clinically relevant associations with survival. 504 patients with...